IO-202 Antibody is a research-grade biosimilar monoclonal antibody. It is a human IgG4, kappa antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% purity as determined by SDS-PAGE. For research use only.
Leukocyte immunoglobulin-like receptor subfamily B member 4 (CD85k/LILRB4) is a ~49 kDa protein. Inhibitory receptor involved in the down-regulation of the immune response and the development of immune tolerance. Receptor for FN1. Receptor for apolipoprotein APOE. Receptor for ALCAM/CD166. Inhibits receptor-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.
Product Name:
IO-202 Antibody
SKU:
GXBS00857
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
CD85 antigen-like family member K
Isotype:
IgG4, kappa
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FACS, Functional assay, Research in vivo
Expression Host:
Mammalian cells
Synonyms:
IO-202, IO202, IO202
Biological Activity:
IO-202 reverses AML cell-mediated T-cell suppression and activates T-cell cytotoxicity against leukemic cells in vitro via high-affinity binding to human LILRB4 and blockade of APOE-mediated LILRB4 activation [1]. IO-202 (15 ug/mL; 2 days) enhances DC activation (increased CD86 and HLA-DR expression) and reduces a tolerogenic phenotype (decreased CD209 expression) when used to treat healthy human donor monocyte-derived dendritic cells during LPS stimulation [3]. IO-202 (15 ug/mL; 2 days during Mo-DC culture, 4 days during T cell co-culture) enhances DC activation marker expression, IL-12 production, and T cell-derived IFNγ production when used to treat human monocyte-derived dendritic cells during CD40L-induced maturation/activation and subsequent allogeneic T cell co-culture, but has no effect on immature Mo-DCs [3]. . IO-202 (10 mg/kg; administered on day 10 and day 20 post tumor implant) combined with 10 Gy radiation therapy induces potent tumor growth inhibition and rebalances the tumor immune infiltrate toward a pro-inflammatory phenotype in a transgenic mouse Lewis lung carcinoma model [3]. . Reduced the frequencies of myeloid-derived suppressor cells (including PMN-MDSCs) among tumor-infiltrating leukocytes. Increased the frequencies of conventional CD4+ T cells and NKT cells among tumor-infiltrating leukocytes. Decreased the expression of the anti-inflammatory marker CD206 on tumor-associated macrophages (TAMs).
Purity:
>95% purity as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
